Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

February 10, 2026 - 22:13

ALAMEDA, Calif., February 10, 2026 – Exelixis, Inc. has announced its financial results for the fourth quarter and the full fiscal year of 2025. The company also provided a comprehensive corporate update, detailing significant progress across its commercial portfolio, clinical development, and research pipeline.

The financial report highlighted robust revenue growth, driven primarily by the continued strong performance of its flagship oncology therapies. This solid financial foundation is enabling the company to aggressively reinvest in its future. A key focus remains on expanding the therapeutic reach of its core cancer treatments through a strategy of combination studies and additional indications.

Beyond its commercial success, Exelixis outlined a series of important clinical milestones anticipated in the coming year. The update emphasized advancements in its diverse pipeline, which includes several novel compounds in earlier stages of development. These investigational therapies span various mechanisms of action, aiming to address unmet needs in oncology.

Company leadership expressed confidence that the execution of its strategic plan, combining sustained commercial execution with disciplined research and development, positions Exelixis for long-term growth. The integrated strategy is designed to deliver new treatment options for patients while building value. The latest financial results and operational progress underscore the company's ongoing commitment to advancing the standard of care in cancer treatment.